早年獲維港投資參投 美國減肥藥開發商Carmot獲羅氏27億美元收購
瑞士羅氏藥廠(Roche)宣布斥27億美元收購美國減肥藥開發商Carmot Therapeutics,挑戰丹麥Novo Nordisk及禮來(Eli Lilly)(LLY.US)在減肥藥市場的領導地位。
羅氏稱,在27億美元協議預付額之外,倘達至特定里程碑,Carmot股本權益持有人可以獲得最多4億美元款額。
羅氏稱,收標目的旗下CT-388的一期臨床結果理想,準備用於第二階段人體臨床測試。CT-388屬於雙重GLP-1/GIP受體激動劑,與禮來的Zepbound屬同一品種。
去年羅氏在阿斯海默症及癌症免疫治療藥品後期階段臨床遇到重大挫折,羅氏現任行政總裁Thomas Schinecker自3月上任以來,快速訂立多宗交易,重建羅氏藥品開發管線。
本地傳媒報道,Carmot於2017年底獲長和系創辦人李嘉誠旗下維港投資牽頭參與B輪融資。而Carmot Therapeutics於上月提交的招股文件顯示,維港投資創辦人周凱旋個人持有該減肥藥研發公司的9.32%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.